Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-07-15
1999-04-06
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514538, 560 34, 562439, C07C27510, A61K 31415
Patent
active
058919120
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/JP95/02236 filed Nov. 1, 1995, published as WO96/14293 May 17, 1996.
TECHNICAL FIELD
The present invention relates to novel 1,3-dialkylurea derivatives having a hydroxyl group which have inhibitory effects on endopeptidase 24.11 and are useful as therapeutic agents for cardiovascular disease such as heart failure and hypertension, renal disease such as renal failure, gastroenteric disorder such as diarrhea and hyperchlorhydria, endocrine and metabolic disease such as obesity, and autoimmune disease such as rheumatic disease, and as analgestics for myosalgia, migraine, etc.
BACKGROUND ART
Endopeptidase 24.11, which is one of neutral endopeptidases, is metal-containing neutral peptidase which is required to contain zinc in its active center and it is also called enkephalinase or an antigen of acute lymphoblast leukemia (CD10).
Endopeptidase 24.11 is an enzyme which distributes widely, for example, in kidney, lung, central nervous system, intestinal canal, neutrophil, fibroblast, vascular endothelial cell, etc. and hydrolyzes many physiologically active peptides such as artial natriuretic polypeptide (ANP), enkephaline, bradykinin and substance P. Therefore, endopeptidase 24.11 is known to take part in various biological functions and to exhibit various therapeutic effects by inhibiting the above-mentioned enzymatic activity.
These effects are exemplified by an effect on cardiovascular disease such as heart failure indicating symptoms of edema and hypertension, an effect on renal disease such as renal failure indicating symptoms of edema and an increase of ascites, an effect on gastroenteric disorder such as diarrhea and hyperchlorhydria, an analgestic effect, an effect on endocrine and metabolic disease such as obesity, and an effect on autoimmune disease such as rheumatic disease.
Substances inhibiting endopeptidase 24.11 are described below in more detail.
The following effects of compounds inhibiting endopeptidase 24.11 have been observed. An increasing effect of total urine volume and urinary sodium excretion has been observed on heart failure models by rapid ventricular pacing method (J. Cardiovasc. Pharmacol., 19, 635-640 (1992)). An increasing effect of urinary ANP excretion and urinary cyclic GMP excretion has been observed (J. Pharmacol. Exp. Ther., 266, 872-883 (1993)). A hypotensive effect has been observed using spontaneously hypertensive rats or deoxycorticosteron acetate induced hypertensive rats (J. Pharmacol. Exp. Ther., 265, 1339-1347 (1993)). An increasing effect of urinary sodium excretion has been observed using rats subjected to five-sixths renal ablation (Circ. Res., 65, 640-646 (1989). An inhibitory effect, which is derived from the effect on the central nervous system, upon pentagastrin-stimulated gastric secretion has been observed (Eur. J. Pharmacol., 154, 247-254 (1988). An improvement effect of acute diarrhea caused by castor oil has been observed (Gut, 33, 753-758 (1992)). An analgestic effect has been observed by the tail-withdrawal test and the hotplate jump test (Nature, 288, 286-288 (1980). In addition, since bonbesin (Proc. Natl. Acad. Sci., 88, 10662-10666 (1991)), which is known as one of substrates of endopeptidase 24.11, has been reported to reduce food intake (J. Clin. Endocrinol. Metab., 76, 1495-1498 (1993)), a compound inhibiting endopeptidase 24.11 is expected to be a therapeutic agent for endocrine and metabolic disease such as obesity. Since an endopeptidase 24.11 activity in blood and synovial fluid has been reported to be higher in patients with rheumatoid arthritis than in healthy men and patients with osteoarthritis (Rheumatol. Int., 13, 1-4 (1993)), a compound inhibiting endopeptidase 24.11 is expected to be a therapeutic agent for autoimmune disease where an immune function is lowered such as rheumatic disease.
A structural feature of the present invention is that 1,3-dialkylurea has carboxyl groups at the ends of both alkylene chains and a hydroxyl group at one alkylene chain. Prior art is explained below from the stan
REFERENCES:
patent: 4515803 (1985-05-01), Henning et al.
patent: 4757050 (1988-07-01), Natarajan et al.
patent: 5475027 (1995-12-01), Talley et al.
Pavel Majer et al., "A Safe and Efficient Method for Preparation of N,N'-Unsymmetrically Disubstituted Ureas Utilizing Triphosgene", Apr. 8, 1994, pp. 1937-1938, J. Org. Chem., vol. 59, No. 7.
Australian Patent Abstract No. 73833/87, P. Raddatz et al., Dec. 7, 1987.
M.A. Fitzpatrick et al., "Acute Hemodynamic, Hormonal, and Renal Effects of Neutral Endopeptidase Inhibition in Ovine Heart Failure", (1992), pp. 635-640, J. of Cardiovasc.Pharmacol., 19.
Andrea A. Seymour et al., "Systemic Hemodynamics, Renal Function and Hormonal Levels during Inhibition of Neutral Endopeptidase 3.4.24.11 and Angiotensin-Converting Enzyme in Conscious Dogs with Pacing-Induced Heart Failure", (1993), pp. 872-883, J. Pharmacol. Exp. Ther., 266.
I. Pham et al., "Effects of Converting Enzyme Inhibitor and Neutral Endopeptidase Inhibitor on Blood Pressure and Renal Function in Experimental Hypertension", (1993), pp. 1339-1347, J. Pharmacol. Exp. Ther., 265.
Helen M. Lafferty et al., "Enkephalinase Inhibition Increase Plasma Atrial Natriuretic peptide Levels, Glomerular Filtration Rate, and Urinary Sodium Excretion in Rate With Reduced Renal Mass", (1989), pp. 640-646, Circ. Res., 65.
Maria Chicau-Chovet et al., "Thiorphan and acetorphan inhibit gastric secretion by a central, non-opioid mechanism in the rat", (1988), pp. 247-254, Eur. J. Pharmacol., 154.
Ph. Baumer et al., "Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea", (192), pp. 753-758, Gut., 33.
B.P. Roques et al., "The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice", (1980), pp. 286-288, Nature, 288.
Margaret A. Shipp et al., "CD10
eutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung", (1991), pp. 10662-10666, Proc. Natl. Acad. Sci., 88.
R.J. Lieverse et al., "Bombesin Reduces Food Intake in Lean Man by a Cholecystokinin-Independent Mechanism", (1993), pp. 1495-1498, J. Clin. Endocrinol. Metab., 76.
M. Matucci-Cerinic et al., "Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?", (1993), pp. 1-4, Rheumatol. Int., 13.
Fujimura Ken-ichi
Fujita Yuko
Kawashima Yoichi
Miyawaki Nobuaki
Suhara Hiroshi
Gerstl Robert
Santen Pharmaceutical Co. Ltd.
LandOfFree
1,3-dialkylurea derivatives having a hydroxyl group does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-dialkylurea derivatives having a hydroxyl group, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-dialkylurea derivatives having a hydroxyl group will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371784